Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Sees Large Drop in Short Interest

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the target of a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 264 shares, a drop of 97.3% from the December 31st total of 9,733 shares. Based on an average trading volume of 27,414 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 27,414 shares, the days-to-cover ratio is presently 0.0 days.

Matinas Biopharma Trading Up 0.7%

NYSEAMERICAN MTNB traded up $0.01 during trading on Wednesday, reaching $0.73. The company’s stock had a trading volume of 7,627 shares, compared to its average volume of 35,507. The firm has a 50 day moving average price of $0.71 and a 200 day moving average price of $1.24. Matinas Biopharma has a 12 month low of $0.47 and a 12 month high of $3.09. The firm has a market capitalization of $4.65 million, a price-to-earnings ratio of -0.21 and a beta of 1.28.

Matinas Biopharma (NYSEAMERICAN:MTNB) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.